Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: The intergroup trial (RTOG 98-11)

Cancer

Volumn 116, Issue 17, 2010, Pages 4007-4013

  Ajani, Jaffer A ^a   Winter, Kathryn A ^b   Gunderson, Leonard L ^c   Pedersen, John ^d   Benson III, Al B ^e   Thomas Jr , Charles R ^f   Mayer, Robert J ^g   Haddock, Michael G ^h   Rich, Tyvin A ⁱ   Willett, Christopher G ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c MAYO CLINIC   (United States)

^d CROSS CANCER INSTITUTE   (Canada)

^e NORTHWESTERN UNIVERSITY   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

^j DUKE UNIVERSITY   (United States)

more..

Author keywords

Anal cancer; Clinical biology; Prognostic factors; Prospective database; Survival

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN C; ANTINEOPLASTIC AGENT;

ADULT; ANUS CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEGAVOLTAGE RADIOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; TREATMENT DURATION; TUMOR VOLUME; ANUS NEOPLASMS; FACTUAL DATABASE; LYMPH NODE METASTASIS; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); SEX DIFFERENCE;

ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; PROGNOSIS; SEX FACTORS;

EID: 77956870017     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25188     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51:1826-1829. (Pubitemid 13093950)
3. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914-1921.
4. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy5-fluorouracil and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996;348:1049-1054.
5. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040-2049. (Pubitemid 27209535)
6. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14: 2527-2539.
7. Boman BM, Moertel CG, O'Connell MJ, et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer. 1984;54:114-125.
8. Das P, Crane CH, Ajani JA. Current treatment for localized anal carcinoma. Curr Opin Oncol. 2007;19:396-400. (Pubitemid 46883533)
9. Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68:794-800.
10. Greenall MJ, Quan SH, Urmacher C, DeCosse JJ. Treatment of epidermoid carcinoma of the anal canal. Surg Gynecol Obstet. 1985;161:509-517. (Pubitemid 16172267)
11. Sato H, Koh PK, Bartolo DC. Management of anal canal cancer. Dis Colon Rectum. 2005;48:1301-1315.
12. Peiffert D, Bey P, Pernot M, et al. Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys. 1997;37:313-324.
13. Longo WE, Vernava AM III, Wade TP, Coplin MA, Virgo KS, Johnson FE. Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy. Ann Surg. 1994;220:40-49.
14. Sischy B, Doggett RL, Krall JM, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Inst. 1989; 81:850-856. (Pubitemid 19147389)
15. Nilsson PJ, Svensson C, Goldman S, Ljungqvist O, Glimelius B. Epidermoid anal cancer: a review of a populationbased series of 308 consecutive patients treated according to prospective protocols. Int J Radiat Oncol Biol Phys. 2005; 61:92-102. (Pubitemid 40039110)
16. Svensson C, Goldman S, Friberg B. Radiation treatment of epidermoid cancer of the anus. Int J Radiat Oncol Biol Phys. 1993;27:67-73. (Pubitemid 23270658)
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Stat Assoc. 1958;53:457-481.
18. Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1996;60:163-170.
19. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
20. Gray RJ. A class of K-samples test for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16: 1141-1154.
21. Ajani JA, Winter KA, Gunderson LL, et al. US Intergroup Anal Carcinoma Trial: Tumor Diameter Predicts for Colostomy. J Clin Oncol. 2009;27:1116-1121.
22. Bruland O, Fluge O, Immervoll H, et al. Gene expression reveals 2 distinct groups of anal carcinomas with clinical implications. Br J Cancer. 2008;98:1264-1273. (Pubitemid 351481671)
23. Schwarz JK, Siegel BA, Dehdashti F, Myerson RJ, Fleshman JW, Grigsby PW. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys. 2008;71:180-186. (Pubitemid 351492591)
24. Piperkova E, Raphael B, Altinyay M, et al. Impact of PET/ CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review. J BUON. 2006;11:523-527. (Pubitemid 46729870)
25. Nguyen BT, Joon DL, Khoo V, et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol. 2008;87:376-382.